in force 2024-07-09 MODIFIED+76 −294§
Amended by Regulation (EU) 2024/1623 32024R1623
applies from: unknown (the text changed beyond its dates, so no date that moved can be read as the application date)
dates added to the text: 2025-12-31 · dates removed: 2020-01-01, 2020-12-31, 2021-01-01, 2021-12-31, 2022-01-01, 2022-12-31
The heading no longer refers to the COVID-19 pandemic, and paragraph 1 now sets the period of temporary treatment as running until 31 December 2025 rather than from 1 January 2020 to 31 December 2022.
Paragraph 2 previously set out three separate factors f of 1, 0.7 and 0.4 applicable across three sub-periods from 2020 to 2022, whereas it now provides a single factor f of 1 applicable until 31 December 2025, removing the earlier tiered reduction and its associated sub-points (a), (b) and (c).
Cited: Art. 468, v1 · Art. 468, v2
text before / after
02013R0575-20240109 → 02013R0575-20240709
Article 468
Temporary treatment of unrealised gains and losses measured at fair value through other comprehensive income in view of the COVID-19 pandemic
1. By way of derogation from Article 35, during the period from 1 January 2020 to until 31 December 2022 2025 (the period of temporary treatment), institutions may remove from the calculation of their Common Equity Tier 1 items the amount A, determined in accordance with the following formula:
A = a · f
where:
a
= the amount of unrealised gains and losses accumulated since 31 December 2019 accounted for as fair value changes of debt instruments measured at fair value through other comprehensive income in the balance sheet, corresponding to exposures to central governments, to regional governments or to local authorities referred to in Article 115(2) of this Regulation and to public sector entities referred to in Article 116(4) of this Regulation, excluding those financial assets that are credit-impaired as defined in Appendix A to the Annex to Commission Regulation (EC) No 1126/2008 (Annex relating to IFRS 9); and
f
= the factor applicable for each reporting year during the period of temporary treatment in accordance with paragraph 2.
2. Institutions shall apply the following factors factor f with a value equal to 1 until 31 December 2025 to calculate the amount A referred to in paragraph 1:
(a) 1 during the period from 1 January 2020 to 31 December 2020;
(b) 0,7 during the period from 1 January 2021 to 31 December 2021;
(c) 0,4 during the period from 1 January 2022 to 31 December 2022. 1.
3. Where an institution decides to apply the temporary treatment set out in paragraph 1, it shall inform the competent authority of its decision at least 45 days before the remittance date for the reporting of the information based on that treatment. Subject to the prior permission of the competent authority, the institution may reverse its initial decision once during the period of temporary treatment. Institutions shall publicly disclose if they apply that treatment.
4. Where an institution removes an amount of unrealised losses from its Common Equity Tier 1 items in accordance with paragraph 1 of this Article, it shall recalculate all requirements laid down in this Regulation and in Directive 2013/36/EU that are calculated using any of the following items:
(a) the amount of deferred tax assets that is deducted from Common Equity Tier 1 items in accordance with point (c) of Article 36(1) or risk weighted in accordance with Article 48(4);
(b) the amount of specific credit risk adjustments.
When recalculating the relevant requirement, the institution shall not take into account the effects that the expected credit loss provisions relating to exposures to central governments, to regional governments or to local authorities referred to in Article 115(2) of this Regulation and to public sector entities referred to in Article 116(4) of this Regulation, excluding those financial assets that are credit-impaired as defined in Appendix A to the Annex relating to IFRS 9, have on those items.
5. During the periods set out in paragraph 2 of this Article, in addition to disclosing the information required in Part Eight, institutions that have decided to apply the temporary treatment set out in paragraph 1 of this Article shall disclose the amounts of own funds, Common Equity Tier 1 capital and Tier 1 capital, the total capital ratio, the Common Equity Tier 1 capital ratio, the Tier 1 capital ratio, and the leverage ratio they would have in case they were not to apply that treatment.